LATEST ALERTS
Comments by the chair of the UK Committee on Toxicity (COT) about reactions to CBD have stirred up a hornet’s nest – but the furore suggests a misunderstanding of what he actually said
Kanavape founder Sebastien Beguerie talks with CannIntelligence podcast host Tiziana Cauli about his judicial battle leading to a crucial European Court of Justice ruling which established CBD legal status across Europe
Cannabis companies are looking to get Google certification as part of the tech giant’s update on the use of Google Ads for CBD products in parts of the US
The US Food and Drug Administration (FDA) has issued a final guidance document for the development of medical drugs containing cannabis
CBD company Chanelle McCoy Health has received approval to start a trial which may allow it to sell its CBD sleeping aid as an over-the-counter (OTC) drug in Australian pharmacies
The recreational reputation of synthetic cannabinoids – synthetic cannabinoid receptor agonists (SCRAs) – precedes them, leading to restrictions on use and even research
Despite what its authors claim, a new and widely reported study fails to establish that the analgesic properties of cannabis can be largely attributable to the placebo effect
New research suggests that the effect of cannabis on dopamine may help to treat certain symptoms of bipolar disorder, with a reduced tendency to engage in risky behaviours and some improvement in cognitive ability
CannIntelligence’s global CBD regulatory tracker offers a deep analysis of the regulations and proposals in over 50 countries, for nine major regulatory areas: hemp cultivation, processing, flower, extracts, food, cosmetics, vaping, pet food and import/export.
Legal hurdles impeding recreational cannabis legalisation in Mexico are expected to continue through 2024, industry members told CannIntelligence during the CannaMexico conference last month
The UK Advertising Standards Authority (ASA) has taken action on CBD product marketing, targeting a series of advertorials produced by Consumer Logic Research specifically promoting two brands
The UK is lagging behind other major markets in the world on research into the benefits of medicinal cannabis, according to a scientist specialising in the area
A major new study into the impact of cannabis on the brain has attracted controversy and accusations of bias from within the industry before it even begins
Smoking cigarettes is going out of fashion, but having smoked cannabis is becoming much more common in the US, according to recent research conducted by analytics and polling firm Gallup
Reducing opioid dependence is a primary goal of medical cannabis programmes, but there remains a need for rigorous science when making decisions about the interaction between cannabis and opioid use for pain
A recent study has shown that CBD can reduce the psychoactive effects of THC – a discovery which could advance the clinical application of medical cannabis
As the US midterm elections approach, questions are being raised about the actions the Biden administration has taken to meet campaign promises regarding drug reform
The Biden Administration recently released a memorandum requiring research receiving federal funds to be made available to the public without charge. But what effect will this have on cannabis research?
A new conceptual inhaler designed around the idea of controlled microdosing could eventually lead to a product capable of administering precise amounts of active ingredients such as CBD, nicotine or even psychedelics
US law enforcement is working alongside toxicologists and cannabis breathalyser developer Cannabix Technologies to test and compare various methods of detecting cannabis intoxication
The US Drug Enforcement Administration (DEA) has issued a pre-solicitation notice to approved medical cannabis producers, the next step in securing new suppliers of cannabis for research purposes after a monopoly was ended
A study published this month provides further evidence that cannabis could be helpful in treating severe late-stage Covid-19
It looks like there will be no easy or quick solutions to addressing the data gaps the European Food Safety Authority (EFSA) requires to reach a conclusion on the safety of CBD as an ingestible ingredient
The European Food Safety Authority wants more safety data before it approves CBD products as novel food. This is what it wants to know, and why, along with a summary of the science on each point
Germany should plan ahead to avoid problems which have plagued governments that have already legalised recreational cannabis on top of medical cannabis
“It’s a myth that cannabis relieves pain,” declared the Daily Mail. But that is not what the study it was reporting said at all
While cannabis use is now legal in many US states, there is as yet no reliable test to determine whether, or how far, a user may be “under the influence”
Lausanne could become the second Swiss city after Basel to launch a recreational cannabis trial this year. But while Basel’s pilot will involve just 400 participants, Lausanne is aiming for triple that number
Companies are trying new ways to reach cannabinoid customers in severely restricted Australia, but they must be careful not to fall foul of strict guidelines that separate promoting from simply informing the public about prescription goods
A six-year study of young adult behaviour reveals that when and where cannabis use is legalised, young people’s use of alcoho. and tobacco drops – and so does the use, and misuse, of pain-relieving prescription drugs
Strangely, Brexit and then the Covid-19 pandemic have combined to create ideal conditions for the UK to potentially become a leader in psychedelics research
A widespread recall of cannabis concentrates sold for vaping at medical cannabis dispensaries in the US state of Pennsylvania has left patients with more questions than answers about who to trust
Members of the Argentina Chamber of Deputies approved a law on 5th May that would establish a legal framework for the production, sale and export of medical cannabis as well as industrial hemp, a decision president Alberto Fernández says could generate 10,000 jobs in the South American country
Clinical trials are investigating how CBD can improve menstrual health and treat conditions such as premenstrual syndrome (PMS) and perhaps even endometriosis
The most common reasons survey respondents gave for using CBD are for treating anxiety, managing chronic pain, and easing issues with skin conditions
Basel will start allowing the sale of recreational cannabis through local pharmacies at the end of the summer as the first Swiss city to win the approval of health authorities for the pilot project
Jamaica is attempting to make itself as synonymous with medical-grade psychedelics in the minds of researchers as it is with cannabis production in the minds of many
CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
